High-quality Goal-directed Peritoneal Dialysis- Prescribing Peritoneal Dialysis

Öz

International Society for Peritoneal Dialysis, has published recommendations for prescribing high-quality goal-directed peritoneal dialysis. The recommendations in this guideline emphasized that dialysis competence should be interpreted clinically, rather than targeting only small solute clearance and fluid removal. The guideline emphasizes a person-centered approach with shared decision-making between the individual performing peritoneal dialysis and the clinical care team. In other words, this guideline focuses on the person performing peritoneal dialysis. Prescription of peritoneal dialysis should have the least impact on the living conditions of the person and should provide clinical and biochemical improvement

Anahtar Kelimeler

• Peritoneal dialysis
• individualized treatment
• renal residual function

Yüksek Kaliteli Hedefe Yönelik Periton Diyalizi - Periton diyalizi reçeteleme/ High-quality Goal-directed Peritoneal Dialysis- Prescribing Peritoneal Dialysis

Öz

Uluslararası Periton Diyalizi Derneği, yüksek kaliteli hedefe yönelik periton diyalizi reçetesi için öneriler yayınlamıştır. Bu kılavuzdaki öneriler, diyaliz yeterliliğini sağlamada yalnızca solüt klirensi ve sıvının uzaklaştırılmasını hedeflemek yerine klinik olarak yorumlanması gerektiği vurgulamıştır. Kılavuz, periton diyalizi yapan birey ile klinik bakım ekibi arasında ortak karar verme ile kişi merkezli bir yaklaşımı vurgular. Diğer bir değişle, bu kılavuz periton diyalizi yapan kişiye odaklanmıştır. Periton diyalizi reçetesi kişinin yaşam koşullarını en az etkilemeli, ayrıca klinik ve biyokimyasal düzelme sağlamalıdır..

Anahtar Kelimeler

• Periton diyalizi,
• Bireyselleştirilmiş tedavi
• Renal rezidüel fonksiyon

Kaynakça

1. 1. Sevinç M, Ortaboz M, Ünsal A. Periton diyalizi fizyolojisi ve yöntemleri. Ünsal A, editör. Periton Diyalizi. 1. Baskı. Ankara: Türkiye Klinikleri. 2019;1-5.
2. 2. Kramer A, Boenink R, Stel VS, Santiuste de Pablos C, Tomović F, Golan E, et al. The ERA-EDTA Registry Annual Report 2018: a summary. Clinical Kidney Journal. 2021;14(1):107-123. doi.org/10.1093/ckj/sfaa271.
3. 3. Vaios V, Georgianos PI, Liakopoulos V, Agarwal R. Assessment and management of hypertension among patients on peritoneal dialysis. Clinical Journal of the American Society of Nephrology. 2019;14(2):297-305. doi: 10.2215/CJN.07480618
4. 4. Bozfakıoğlu S. Periton diyalizinin tipleri:Reçetelendirme Prensipleri ve Örnekleri. Periton Diyalizi Başvuru Kitabı. Güneş Tıp Kitabevi. 2019;43-52.
5. 5. Dombros N, Dratwa M, Gokal, R, Heimbürger O, Krediet R, Plum J, et al. European best practice guidelines for peritoneal dialysis. 2 The initiation of dialysis. Nephrology, Dialysis, Transplantation. 2005;(20): Suppl 9:ix8-ix12. doi: 10.1093/ndt/gfi1117.
6. 6. Brown EA, Blake PG, Boudville N, Davies S, de Arteaga J, Dong J, et al. International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Peritoneal Dialysis International. 2020;40(3):244- 253. doi: 10.1177/0896860819895364.
7. 7. Teitelbaum I, Glickman J, Neu A, Neumann J, Rivara MB, Shen J, et al. KDOQI US Commentary on the 2020 ISPD Practice Recommendations for Prescribing High-Quality Goal-Directed Peritoneal Dialysis. American Journal of Kidney Diseases, 2021;77(2):157-171. doi: 10.1053/j.ajkd.2020.09.010.
8. 8. Finkelstein FO, Foo MW. Health-related quality of life and adequacy of dialysis for the individual maintained on peritoneal dialysis. Peritoneal Dialysis International.2020;40(3): 270-273. doi: 10.1177/0896860819893815.

9. 9. Lim HA, Yu Z, Kang AW, Foo MW, Griva K. The course of quality of life in patients on peritoneal dialysis. International Journal of Behavioral Medicine. 2016; 23: 507–514. doi: 10.1007/s12529-015-9521-z.
10. 10. Aguiar R, Pei M, Qureshi AR, Lindholm B. Health‐related quality of life in peritoneal dialysis patients: A narrative review. In Seminars in Dialysis 2019;32(5):452-462. doi: 10.1111/sdi.12770.
11. 11. Bilgic A, Akman B, Sezer S, Ozisik L, Arat Z, Ozdemir FN, et al. Predictors for quality of life in continuous ambulatory peritoneal dialysis patients. Nephrology, 2008;13(7):587-592. doi: 10.1111/j.1440-1797.2008.00970.x.
12. 12. Senol V, Sipahioglu MH, Ozturk A, Argün M, Utaş C. Important determinants of quality of life in a peritoneal dialysis population in Turkey. Renal Failure, 2010;32(10):1196-1201. doi: 10.3109/0886022X.2010.517349.
13. 13. Blake PG, Brown EA. Person-centered peritoneal dialysis prescription and the role of shared decision-making. Peritoneal Dialysis International, 2020;40(3):302-309. doi: 10.1177/0896860819893803.
14. 14. Ankawi G, Woodcock NI, Jain AK, Garg AX, Blake PG. The use of incremental peritoneal dialysis in a large contemporary peritoneal dialysis program. Canadian Journal of Kidney Health and Disease. 016;13(3):2054358116679131. doi: 10.1177/2054358116679131.
15. 15. Wilkie, M. Prescribing peritoneal dialysis–a new guideline from the International Society of Peritoneal Dialysis. Peritoneal Dialysis International. 2020;40(3):243.
16. 16. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrology Dialysis Transplantation. 2005;20(8):1693-701. doi: 10.1093/ndt/gfh856.
17. 17. Udayaraj UP, Steenkamp R, Caskey FJ, Rogers C, Nitsch D, Ansell D, et al. Blood pressure and mortality risk on peritoneal dialysis. American Journal of Kidney Diseases. 2009;53(1):70-78. doi: 10.1053/j.ajkd.2008.08.030.
18. 18. Ortega LM, Materson BJ. Hypertension in peritoneal dialysis patients: epidemiology, pathogenesis, and treatment. Journal of the American Society of Hypertension, 2011;5(3): 128-136. doi: 10.1016/j.jash.2011.02.004.
19. 19. Vongsanim S, Davenport A. Factors associated with systolic hypertension in peritoneal dialysis patients. Journal of Nephrology, 2020;33(2):365-370. doi: 10.1007/s40620-019-00633-y.
20. 20. Sarafidis PA, Persu A, Agarwal R, Burnier M, De Leeuw P, Ferro CJ, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrology Dialysis Transplantation, 2017;32(4): 620-640. doi: 10.1097/HJH.0000000000001283.
21. 21. Kim YL, Van Biesen W. Fluid overload in peritoneal dialysis patients. In Seminars in Nephrology 2017; 37(1):43-53. doi: 10.1016/j.semnephrol.2016.10.006.
22. 22. Kiebalo T, Holotka J, Habura I, Pawlaczyk K. Nutritional status in peritoneal dialysis: nutritional guidelines, adequacy and the management of malnutrition. Nutrients 2020;12(6): 1715. doi: 10.3390/nu12061
23. 23. Salamon KM, Lambert K. Oral nutritional supplementation in patients undergoing peritoneal dialysis: a randomised, crossover pilot study. Journal of Renal Care, 2018;44(2):73-81. doi: 10.1111/jorc.12224.
24. 24. Sahathevan S, Se CH, Ng S, Khor BH, Chinna K, Goh BL, et al. Clinical efficacy and feasibility of whey protein isolates supplementation in malnourished peritoneal dialysis patients: A multicenter, parallel, open-label randomized controlled trial. Clinical Nutrition ESPEN, 2018; 25: 68-77. doi: 10.1016/j.clnesp.2018.04.002.
25. 25. Naeeni AE, Poostiyan N, Teimouri Z, Mortazavi M, Soghrati M, Poostiyan E, et al. Assessment of severity of malnutrition in peritoneal dialysis patients via malnutrition: inflammatory score. Advanced Biomedical Research, 2017; 6:128. doi: 10.4103/abr.abr_554_13.
26. 26. Paniagua R, Amato D, Vonesh E, Guo A, Mujais S. Mexican Nephrology Collaborative Study Group: Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney International. 2005;67(3): 1093–1104. doi: 10.1111/j.1523-1755.2005.00175.x.
27. 27. Bargman JM, Thorpe KE, Churchill DN. CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. Journal of the American Society of Nephrology. 2001;12(10): 2158–2162, 2001. doi: 10.1681/ASN.V12102158.
28. 28. Lew SQ. Maintaining peritoneal dialysis adequacy: The process of incremental prescription. Advances in Peritoneal Dialysis. 2018;34:10-14.
29. 29. Fan L, Steubl D, Inker LA, Tighiouart H, Simon AL, Foster MC, et al. Estimating total small solute clearance in patients treated with continuous ambulatory peritoneal dialysis without urine and dialysate collection. Peritoneal Dialysis International, 2020;40(1), 84-92. doi: 10.1177/0896860819878658.
30. 30. Boudville N, de Moraes TP. 2005 Guidelines on targets for solute and fluid removal in adults being treated with chronic peritoneal dialysis: 2019 update of the literature and revision of recommendations. Peritoneal Dialysis International,. 2020;40(3):254-260. doi: 10.1177/0896860819898307
31. 31. Glavinovic T, Hurst H, Hutchison A, Johansson L, Ruddock N, Perl J. Prescribing high-quality peritoneal dialysis: Moving beyond urea clearance. Peritoneal Dialysis International 2020;40(3):293-301. doi: 10.1177/0896860819893571.
32. 32. Chen CH, Perl J, Teitelbaum I. Prescribing high-quality peritoneal dialysis: The role of preserving residual kidney function. Peritoneal Dialysis International. 2020;40(3):274-281. doi: 10.1177/0896860819893821.
33. 33. Liew A. Prescribing peritoneal dialysis and achieving good quality dialysis in low and low-middle income countries. Peritoneal Dialysis International. 2020;40(3):341-348. doi: 10.1177/0896860819894493.
34. 34. Lee Y, Chung SW, Park S, Ryu H, Lee H, Kim DK, et al. Incremental peritoneal dialysis may be beneficial for preserving residual renal function compared to full-dose peritoneal dialysis. Scientific Reports, 2019;9(1):10105. doi: 10.1038/s41598-019-46654-2.
35. 35. Blake PG, Dong J, Davies SJ. Incremental peritoneal dialysis. Peritoneal Dialysis International, 2020;40(3): 320-326.doi: 10.1177/0896860819895362.
36. 36. Ethier I, Cho Y, Hawley C, Pascoe EM, Viecelli AK, Campbell SB, et al. Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study. PloS one, 2020;15(11): e0242254. doi: 10.1371/journal.pone.0242254.
37. 37. Perl J, Dember LM, Bargman JM, Browne T, Charytan DM, Flythe JE, et al. The use of a multidimensional measure of dialysis adequacy—moving beyond small solute kinetics. Clinical Journal of the American Society of Nephrology, 2017;12(5):839-847. doi: 10.2215/CJN.08460816.
38. 38. Liu XY, Gao XM, Zhang N, Chen R, Wu F, Tao XC, et al. Oral bicarbonate slows decline of residual renal function in peritoneal dialysis patients. Kidney and Blood Pressure Research, 2017;42(3):565-574. https://doi.org/10.1159/000479641.
39. 39. Santos JE, Silva R, Vicente R, Santos I, Coimbra M, Fiel D, et al. The role of incremental peritoneal dialysis among patients on peritoneal dialysis. A longitudinal analysis over 20 years. Portuguese Journal of Nephrology & Hypertension. 2021;35(1):39-45. doi: 10.32932/pjnh.2021.04.113.
40. 40. Chang TI, Oh HJ, Kang EW, Yoo TH, Shin SK, Kang SW, et al. A low serum bicarbonate concentration as a risk factor for mortality in peritoneal dialysis patients. PloS one. 2013;8(12), e82912. doi: 10.1371/journal.pone.0082912.
41. 41. Teitelbaum I. Delivering high-quality peritoneal dialysis: what really matters?. Clinical Journal of the American Society of Nephrology. 2020;15(11):1663-1665. doi: https://doi.org/10.2215/CJN.02930320
42. 42. Morooka H, Yamamoto J, Tanaka A, Inaguma D, Maruyama S. Relationship between mortality and use of sodium bicarbonate at the time of dialysis initiation: a prospective observational study. BMC Nephrology.2021;22(1):1-10. https://doi.org/10.1186/s12882-021-02330-0
43. 43. Hao N, Cheng BC, Yang HT, Wu CH, Lei YY, Chao MC, et al. Time-varying serum albumin levels and all-cause mortality in prevalent peritoneal dialysis patients: a 5-year observational study. BMC Nephrology. 2019;20(1):254. doi: 10.1186/s12882-019-1433-8.
44. 44. Noppakun K, Kasemset T, Wongsawad U, Ruengorn C, Thavorn K, Sood MM, et al. Changes in serum albumin concentrations during transition to dialysis and subsequent risk of peritonitis after peritoneal dialysis initiation: a retrospective cohort study. Journal of Nephrology, 2020;33(6): 1275-1287. doi: 10.1007/s40620-020-00716-1.
45. 45. Mehrotra R, Duong U, Jiwakanon S, Kovesdy CP, Moran J, Kopple JD et al. Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis. American Journal of Kidney Diseases 2011:58(3):418-428. doi: 10.1053/j.ajkd.2011.03.018
46. 46. Chan M, Kelly J, Batterham M, Tapsell L. Malnutrition (subjective global assessment) scores and serum albumin levels, but not body mass index values, at initiation of dialysis are independent predictors of mortality: a 10- year clinical cohort study. Journal of Renal Nutrition. 2012;22:547 –57. doi: 10.1053/j.jrn.2011.11.002.
47. 47. Wang X, Han Q, Wang T, Tang W. Serum albumin changes and mortality risk of peritoneal dialysis patients. International Urology and Nephrology, 2020;52(3):565-571. doi: 10.1007/s11255-020-02389-y.
48. 48. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements. 2012; 2(4):279–335.https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf.
49. 49. Perlman RL, Zhao J, Fuller DS, Bieber B, Li Y, Pisoni RL, et al. International anemia prevalence and management in peritoneal dialysis patients. Peritoneal Dialysis International.2019; 39(6):539-546. doi: 10.3747/pdi.2018.00249.
50. 50. Chen Y, Fang W, Gu L, Cao L, Yan H, Huang J, et al. The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study. International Urology and Nephrology. 2018;50(1):167-171. doi: 10.1007/s11255-017-1722-8.
51. 51. Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K. Association of Hemoglobin and Survival in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology. 2011;6(8):1973–1981. doi: https://doi.org/10.2215/CJN.01050211
52. 52. Hamad A, Hussain ME, Elsanousi S, Ahmed H, Navalta L, Lonappan V, et al. Prevalence and management of hypokalemia in peritoneal dialysis patients in Qatar. International Journal of Nephrology. 2019. https://doi.org/10.1155/2019/1875358
53. 53. Xu Q, Xu F, Fan L, Xiong L, Li H, Cao S, et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality. PLoS ONE. 2014;9(1):e86750. doi: 10.1371/journal.pone.0086750.
54. 54. Torlen K, Kalantar-Zadeh K, Molnar MZ, Vashistha T, Mehrotra R. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Kidney Research and Clinical Practice. 2012;31(2): A73.
55. 55. Chuang YW, Shu KH, Yu TM, Cheng CH, Chen CH. Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. Nephrology, Dialysis, Transplantation. 2009;24(5):1603–1608. doi: 10.1093/ndt/gfn709
56. 56. Goncalves FA, de Jesus JS, Cordeiro L, Piraciaba MCT, de Araujo LK, Martins CSW, et al. Hypokalemia and hyperkalemia in patients on peritoneal dialysis: incidence and associated factors. International Urology and Nephrology. 2020;52(2):393-398. doi: 10.1007/s11255-020-02385-2.
57. 57. Jung JY, Chang JH, Lee HH, Chung W, Kim S. De novo hypokalemia in incident peritoneal dialysis patients: a 1-year observational study. Electrolyte Blood Pressure. 2009;7(2):73–78. doi: 10.5049/EBP.2009.7.2.73
58. 58. Rhee CM, Ayus JC, Kalantar-Zadeh K. Hyponatremia in the Dialysis Population. Kidney International Reports. 2019;4(6):769– 80. doi: 10.1016/j.ekir.2019.02.012.
59. 59. Ravel VA, Streja E, Mehrotra R, Sim JJ, Harley K, Ayus JC, et al. Serum sodium and mortality in a national peritoneal dialysis cohort. Nephrology, Dialysis, Transplantation. 2017;32(7): 1224–33. doi: 10.1093/ndt/gfw254.
60. 60. Chang TI, Kim YL, Kim H, Ryu GW, Kang EW, Park JT, et al. Hyponatremia as a predictor of mortality in peritoneal dialysis patients. PLoS One. 2014;9(10):e111373 https://doi.org/10.1371/journal.pone.0111373.
61. 61. Qiu Y, Ye H, Wang Y, Zhong Z, Li H, Huang F, et al. Age difference in the association between hyponatremia and infectionrelated mortality in peritoneal dialysis patients. Blood Purification, 2020;49(5):631-640. doiI: 10.1159/000505614.
62. 62. Rivara MB, Ravel V, Kalantar-Zadeh K, Streja E, Lau WL, Nissenson AR, et al. Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis. Journal of the American Society of Nephrology. 2015;26(7):1671-1681. doi: 10.1681/ASN.2014050472.
63. 63. Liu CT, Lin YC, Lin YC, Kao CC, Chen HH, Hsu CC, et al. Roles of serum calcium, phosphorus, PTH and ALP on mortality in peritoneal dialysis patients: a nationwide, population-based longitudinal study using TWRDS 2005–2012. Scientific Reports. 2017;7(11):33. https://doi.org/10.1038/s41598-017-00080-4.
64. 64. 64.Yang X, Soohoo M, Streja E, Rivara MB, Obi Y, Adams SV, et al. Serum magnesium levels and hospitalization and mortality in incident peritoneal dialysis patients: a cohort study. American Journal of Kidney Diseases. 2016;68(4):619–627. doi: 10.1053/j.ajkd.2016.03.428.
65. 65. Ye H, Cao P, Zhang X, Lin J, Guo Q, Mao H, et al. Serum magnesium and cardiovascular mortality in peritoneal dialysis patients: A 5-year prospective cohort study. British Journal of Nutrition. 2018;120(4):415-423. doi: 10.1017/S0007114518001599.
66. 66. Wu M, Wu H, Huang X, Ye H, Huang F, Yu X, et al. Associations between serum mineral metabolism parameters and mortality in patients on peritoneal dialysis. Nephrology. 2019;24(11):1148-1156. doi: 10.1111/nep.13535.